Clinical Trial Search

Primary: Post-operative Mean Numeric Pain Scale. — 2.12; 2.32 units on a scale

Primary: Military to Civilian Questionnaire — 27; 24.7 score on a scale

Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 3; 3; 5 Participants

Primary: Visual Analogue Scale for Breast and Nipple Pain Severity — 39.43; 36.55; 44.31; 36.93 units on a scale — p=<0.0045

Primary: Change in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Score — 3.0; -2.5; -2.5; 1.5 score on a scale — p=0.008

Primary: Asthma Exacerbations During 52 Weeks Preceding Treatment Initiation (as Assessed at Baseline) and at the 24th and 52nd Week of the Treatment — 3; 0; 0 number of asthma…

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12 — 0.309; 0.109 Liter — p=<0.0001

Primary: Binocular Corrected Distance Visual Acuity (CDVA) — -0.03; -0.03 logMAR

Primary: Part 1: Change From Mannitol Baseline Forced Expiratory Volume in the First Second (FEV1) Area Under the Curve (AUC [0-60 Min]) Post-mannitol Challenge 1…

Primary: Pain Tolerance — 44.72; 45.09 seconds

Primary: Stone Free Rate (SFR) - Zero Fragments — 48; 49 % subjects

Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001

Primary: [Module C] Objective Response (OR) — 14.3; 23.3; 0.0; 3.3 percentage of participants

Primary: Quality of Life of Patients Participating in the 12-week Adapted Physical Activity Program. — 117.6 score on a scale

Primary: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. — 17 Participants